ABIOMED INC ABIOMED ORD SHS 

$381.02
38
+$0.00+0%星期四 16:24

統計

當日最高
-
當日最低
-
52週高點
-
52週低點
-
成交量
-
平均成交量
-
市值
0
本益比
1.28
股息殖利率
-
股息
-

財報

10月30日預期
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
1.19
1.57
1.94
2.32
預期EPS
不適用
實際EPS
不適用

財務

13.23%利潤率
有盈利
2016
2017
2018
2019
2020
2021
1.03B營收
136.51M淨利

競爭對手

此清單為基於近期市場事件的分析。並非投資建議。

關於

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.
顯示更多
執行長
Mr. Michael R. Minogue
員工
2003
國家
美國
ISIN
US0036541003
WKN
000873886

上市

0 則留言

分享你的想法

常見問題

ABIOMED INC ABIOMED ORD SHS 今天的股價是多少?▼
0H7S.LSE 目前價格為 $381.02 USD,過去 24 小時上漲了 +0%。在圖表上更密切關注 ABIOMED INC ABIOMED ORD SHS 股價表現。
ABIOMED INC ABIOMED ORD SHS 的股票代號是什麼?▼
根據交易所不同,股票代號可能會有所差異。例如,在 London Exchange 交易所,ABIOMED INC ABIOMED ORD SHS 的股票以代號 0H7S.LSE 進行交易。
ABIOMED INC ABIOMED ORD SHS 去年的營收是多少?▼
ABIOMED INC ABIOMED ORD SHS 去年的營收為 1.03BUSD。
ABIOMED INC ABIOMED ORD SHS 去年的淨利是多少?▼
0H7S.LSE 去年的淨收益為 136.51MUSD。
ABIOMED INC ABIOMED ORD SHS 有多少名員工?▼
截至 2026年10月27日,公司共有 2,003 名員工。
ABIOMED INC ABIOMED ORD SHS 位於哪個產業?▼
ABIOMED INC ABIOMED ORD SHS從事於Other產業。
ABIOMED INC ABIOMED ORD SHS 何時完成拆股?▼
ABIOMED INC ABIOMED ORD SHS 最近沒有進行任何拆股。
ABIOMED INC ABIOMED ORD SHS 的總部在哪裡?▼
ABIOMED INC ABIOMED ORD SHS 的總部位於 美國 的 Danvers。